Cypher Genomics Inc. and Sequenom Inc. (Nasdaq: SQNM) announced a development agreement for next generation of noninvasive prenatal tests.
Sequenom will use Cypher's genome interpretation technology, called Mantis, to advance analysis of clinically relevant fetal subchromosomal variants detected in maternal blood. Often not detected until after birth, subchromosomal variants comprise greater than 50 percent of rare chromosomal abnormalities beyond the more common aneuploidies and are associated with significant risks of morbidity and mortality.
Sequencing-based testing has been largely focused on whole chromosome events. Subchromosomal structural variations, such as microdeletions and microduplications, are more difficult to detect and classify but represent a larger proportion of clinically relevant abnormalities. Cypher's proprietary Mantis technology could help overcome the genomic interpretation challenge and can potentially support Sequenom's development of a next generation NIPT offering.
3595 John Hopkins Ct.
San Diego, CA 92121